Apogee Therapeutics APGE 深 沪
已收盘 08-29 16:00:00 美东时间
36.37
-0.250
-0.68%
华盛通- 最 高37.35
- 今 开36.65
- 成交量 51.66万股
- 最 低 35.68
- 昨 收 36.62
- 总市值 21.68亿
- 52周最高 63.50
- 市盈率 静 --
- 换手率 0.87%
- 52周最低 26.20
- 委 比 -86.36%
- 总股本 5959.64万
- 历史最高 72.29
- 量 比 1.38
- 振 幅 4.56%
- 历史最低 14.19
- 每 手 1
- 风险率 7.45%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多B of A Securities Maintains Buy on Apogee Therapeutics, Raises Price Target to $87
B of A Securities analyst Tim Anderson maintains Apogee Therapeutics (NASDAQ:APGE) with a Buy and raises the price target from $78 to $87.
08-28 23:54
Apogee Therapeutics reports Q2 results
Apogee Therapeutics press release (NASDAQ:APGE): Q2 Net loss was $66.1 million for the quarter ended June 30, 2025, compared to a net loss of $33.8 million for the quarter ended June 30, 2024. Cash, c...
08-12 02:00
Apogee Therapeutics Q2 EPS $(1.13) Beats $(1.16) Estimate
Apogee Therapeutics (NASDAQ:APGE) reported quarterly losses of $(1.13) per share which beat the analyst consensus estimate of $(1.16) by 2.84 percent. This is a 88.33 percent decrease over losses of $(0.60) per share
08-11 19:35
Apogee Therapeutics Provides Pipeline Progress and Reports Second Quarter 2025 Financial Results
Apogee Therapeutics reported positive 16-week Phase 2 Part A data for APG777, a potentially best-in-class anti-IL-13 antibody for moderate-to-severe atopic dermatitis (AD). The drug met all primary and key secondary endpoints, demonstrating significant efficacy and reduced injection burden for patients, potentially requiring 2-4 injections per year versus 26 for current treatments. Part B of the APEX trial is on track for a mid-2026 readout, with...
08-11 11:00
多面手OX40：炎症、自免、肿瘤治疗新希望
（来源：药研网） 前言 2025年7月2日，创响生物宣布，抗OX40单抗IMG-007在中重度特应性皮炎（AD）国际多中心IIb期研究（ADAPTIVE，NC...
07-23 07:50
美股周涨跌榜 | 加密货币概念股SharpLink周涨71%；CoreWeave周内暴跌23.8%，分析师喊话公司估值似乎过高
加密货币股SharpLink周涨71%；MP周涨超41%，公司与美国国防部签署战略合作协议；CoreWeave周内暴跌23.8%，分析师喊话公司估值似乎过高>>
07-12 10:03
Apogee Therapeutics Announces Positive 16-Week Data from Phase 2 APEX Clinical Trial of APG777, its Potentially Best-in-Class Anti-IL-13 Antibody, in Moderate-to-Severe Atopic Dermatitis
Apogee Therapeutics' APG777 achieved significant results in Phase 2 APEX Part A trial for moderate-to-severe atopic dermatitis, with 66.9% of patients reaching EASI-75 and a 71.0% EASI reduction at Week 16. The drug showed a favorable safety profile, potentially best-in-class efficacy, and a promising exposure-response relationship. APEX Part B, testing higher doses, is expected to read out mid-2026, with a Phase 3 trial planned for 2026. APG279,...
07-07 10:00
Apogee Therapeutics to Host Conference Call to Report Part A 16-Week Data from the Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis on July 7, 2025
Apogee Therapeutics will announce Phase 2 APEX Part A 16-week data for APG777 on July 7, 2025, followed by a webcast at 8:00 a.m. ET. The webcast will discuss results related to the treatment of inflammatory and immunology conditions like atopic dermatitis, asthma, and COPD. The live event can be accessed via the provided links, with a replay available afterward.
07-06 22:00
美股大行评级 | 潜在涨幅336.36%！Canaccord Genuity上调ATAI Life Sciences目标价至12美元，维持"买入"评级
Redburn Atlantic：下调Adobe(ADBE)评级至"卖出"，目标价从420美元降至280美元
07-03 11:01
Guggenheim Reiterates Buy on Apogee Therapeutics, Maintains $116 Price Target
Guggenheim analyst Seamus Fernandez reiterates Apogee Therapeutics (NASDAQ:APGE) with a Buy and maintains $116 price target.
07-02 20:37
